The combination regimen comprising gemcitabine and nab*-paclitaxel (GNP) exhibited similar potential with FOLFIRINOX** in downstaging and improving survival rates in pancreatic cancer, according to several studies presented at the ASCO Gastrointestinal Cancers Symposium 2018 (ASCO GI 2018).
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
The combination of nivolumab and ipilimumab demonstrated strong response, progression-free survival (PFS), and overall survival (OS) rates in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic or recurrent colorectal cancer (CRC), results from the phase II CheckMate-142* trial show.
The addition of ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist, to chemotherapy, prolonged progression-free survival (PFS) in individuals with previously untreated metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma, findings from the phase III RAINFALL* trial show.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
Peripheral T cell (PTCL) and natural killer/T cell (NKTCL) non-Hodgkin lymphoma have poor prognoses in elderly adults, though intensive chemotherapy may yield benefit for some, a recent study has found.